SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · PPR

[18F]DED PET Nörodejeneratif Hastalıklarda Reaktif Astroglioz Görüntülemesi: Kavramın Preklinik Kanıtı ve İnsanda İlk Veri

[18F]DED PET Imaging of Reactive Astrogliosis in Neurodegenerative Diseases: Preclinical Proof of Concept and First-in-Human Data

Makine çevirisi · Editoryal inceleme bekliyor

· 2022-12-12

DOI: 10.21203/rs.3.rs-2247888/v1

Erişim kaynaktan kontrol edilmeliPreprintKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Objective: Reactive gliosis is a common pathological hallmark of CNS pathology resulting from neurodegeneration and neuroinflammation. In this study we investigate the capability of a novel monoamine oxidase B (MAO-B) PET ligand to monitor reactive astrogliosis in a transgenic mouse model of Alzheimer`s disease (AD). Furthermore, we performed a pilot study in patients with a range of neurodegenerative and neuroinflammatory conditions. Methods A cross-sectional cohort of 24 transgenic (PS2APP) and 25 wild-type mice (age range: 4.3–21.0 months) underwent 60 min dynamic [ 18 F]D2-deprenyl ([ 18 F]DED), static 18kDa translocator protein (TSPO, [ 18 F]GE-180) and β-amyloid ([ 18 F]florbetaben) PET imaging. Quantification was performed via image derived input function (IDIF, cardiac input), simplified non-invasive reference tissue modelling (SRTM2, DVR) and late-phase standardized uptake value ratios (SUVr). Immunohistochemical (IHC) analyses of glial fibrillary acidic protein (GFAP) and MAO-B were performed to validate PET imaging by gold standard assessments. Patients with Alzheimer’s disease (AD, n = 2), Parkinson’s disease (PD, n = 2), multiple system atrophy (MSA, n = 2), autoimmune encephalitis (n = 1) and oligodendroglioma (n = 1) underwent 60 min dynamic [ 18 F]DED PET and the data were analyzed using equivalent quantification strategies. Results We selected the cerebellum as a pseudo-reference region based on the immunohistochemical comparison of age-matched PS2APP and WT mice. Subsequent PET imaging revealed that PS2APP mice showed elevated hippocampal and thalamic [ 18 F]DED DVR when compared to age-matched WT mice at 5 months (thalamus: +4.3%; p = 0.048), 13 months (hippocampus: +7.6%, p = 0.022) and 19 months (hippocampus: +12.3%, p < 0.0001; thalamus: +15.2%, p < 0.0001). Specific [ 18 F]DED DVR increases of PS2APP mice occurred earlier when compared to signal alterations in TSPO and β-amyloid PET and [ 18 F]DED DVR correlated with quantitative immunohistochemistry (hippocampus: R = 0.720, p < 0.001; thalamus: R = 0.727, p = 0.002). Preliminary experience in patients showed [ 18 F]DED V T patterns, matching the expected topology of reactive astrogliosis in neurodegenerative (AD, PD, MSA) and neuroinflammatory conditions, whereas the oligodendroglioma lesion indicated no altered [ 18 F]DED binding. Conclusion [ 18 F]DED PET imaging is a promising approach to assess reactive astrogliosis in AD mouse models and patients with neurological diseases.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.